Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents
Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents
批准号:
7496377
负责人:
John K Buolamwini
金额:
$7.3万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-02-15 至 2010-01-31
关键词:
AIDS chemotherapyAIDS/HIV problemAcidsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntimalarialsAromatic Polycyclic HydrocarbonsButyric AcidButyric AcidsCarcinogenicity TestsCarcinogensClassClinical TrialsCultured CellsDevelopmentDrug resistanceElectronsEnzymesFaceGoalsGrantHIVHIV IntegraseHIV Integrase InhibitorsHIV Protease InhibitorsHighly Active Antiretroviral TherapyHumanHydrocarbonsIn VitroInhibitory Concentration 50IntegraseIntegrase InhibitorsLife Cycle StagesLightMalariaMethodsModelingModificationMulti-Drug ResistanceMutagenicity TestsMutagensPeripheral Blood Mononuclear CellPharmaceutical PreparationsPublic HealthRNA-Directed DNA PolymeraseResearchTestingTherapeuticTherapeutic IndexToxic effectTumor InitiatorsViralVirusWorkcarcinogenicitycompliance behaviorconceptfollow-uphalofantrineindexinginhibitor/antagonistnovelphenanthrenepreclinical studyscaffoldsmall moleculesuccesstherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our studies on novel small molecules inhibitors of HIV integrase have led to the identification of new potent phenanthrene diketoacid (DKA) HIV integrase inhibitors that also inhibit HIV replication in cell culture, with a selectivity index up to 10. In light of the need for more effective and less toxic anti- HIV drugs, these results appear promising and warrant follow-up optimization and preclinical studies. However, since phenanthrenes are polyaromatic hydrocarbons (PAHs) with potential carcinogenicity we propose to investigate these novel phenanthrene diketoacids for carcinogenicity potential. Our hypothesis going forward is that appropriate substitution with electron withdrawing groups can minimize mutagenicity and produce useful anti-HIV agents. This is supported by the example of the new anti-malarial drug halofantrine, a substituted phenanthrene that is effective against multidrug resistant malaria, and is neither mutagenic nor teratogenic. We thus believe that appropriate substitution of our HIV integrase inhibitory phenanthrene DKAs will make them non-mutagenic and non-carcinogenic. Thus the specific aims of this proposal are: 1) to synthesize and test the IN inhibitory activity of new phenanthrene diketoacids with multiple electron withdrawing substituents and 2) to determine the carcinogenicity potential of the phenanthrene DKAs synthesized in Specific Aim 1. We will use the Ames test for in vitro carcinogenicity testing. The success of this project will provide vital information to decide whether or not to go ahead with optimization of the potent phenanthrene DKA HIV integrase inhibitors that we discovered recently and shown to selectively inhibit HIV replication in human peripheral blood mononuclear cells. If this approach to reducing carcinogenicity is successful it will not only provide a means of eliminating carcinogenicity of the phenanthrene DKAs, but may also provide a general method for reducing the carcinogenicity of PAH containing drugs.
PUBLIC HEALTH RELEVANCE: This project is aimed at investigating whether or not a novel class of potent phenanthrene diketo acid HIV integrase inhibitors that have been shown to suppress HIV viral replication in cell culture, are carcinogenic. The results of the research will determine whether to carry on with further work on optimizing this class of new anti-HIV agents towards AIDS therapeutics development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on Probenecid Prodrugs that Protect against Mitochondrial Toxicity of Tenofovir
-
批准号:10672238
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2022
-
负责人:John K Buolamwini
-
依托单位:
Studies on Probenecid Prodrugs that Protect against Mitochondrial Toxicity of Tenofovir
-
批准号:10548702
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2022
-
负责人:John K Buolamwini
-
依托单位:
Novel Drug Discovery for AD Targeting Ryanodine Calcium Channels
-
批准号:9028443
-
项目类别:
-
资助金额:$195.0万
-
财政年份:2016
-
负责人:John K Buolamwini
-
依托单位:
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
-
批准号:8463573
-
项目类别:
-
资助金额:$26.43万
-
财政年份:2012
-
负责人:John K Buolamwini
-
依托单位:
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
-
批准号:8814250
-
项目类别:
-
资助金额:$24.42万
-
财政年份:2012
-
负责人:John K Buolamwini
-
依托单位:
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
-
批准号:8628851
-
项目类别:
-
资助金额:$12.31万
-
财政年份:2012
-
负责人:John K Buolamwini
-
依托单位:
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
-
批准号:8955457
-
项目类别:
-
资助金额:$17.14万
-
财政年份:2012
-
负责人:John K Buolamwini
-
依托单位:
A Targeted Preemptive Approach to Addressing Mitochondrial Toxicity of Nucleoside
-
批准号:8332894
-
项目类别:
-
资助金额:$28.62万
-
财政年份:2012
-
负责人:John K Buolamwini
-
依托单位:
Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV Agents
-
批准号:7756787
-
项目类别:
-
资助金额:$24.46万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Inhibitors of the ENT4 Adenosine Transporter for Cardioprotection
-
批准号:7907749
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Mechanism of Chemoprevention Action and SAR of a Tetrahydroisoquinoline Riboside
-
批准号:7777887
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV Agents
-
批准号:7924092
-
项目类别:
-
资助金额:$18.34万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Inhibitors of the ENT4 Adenosine Transporter for Cardioprotection
-
批准号:7741175
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Mechanism of Chemoprevention Action and SAR of a Tetrahydroisoquinoline Riboside
-
批准号:7666618
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2009
-
负责人:John K Buolamwini
-
依托单位:
Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents
-
批准号:7567545
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2008
-
负责人:John K Buolamwini
-
依托单位:
DEVELOPMENT OF NOVEL CHEMOPRVENTIVE AGENTS
-
批准号:7321590
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2007
-
负责人:John K Buolamwini
-
依托单位:
DEVELOPMENT OF NOVEL CHEMOPRVENTIVE AGENTS
-
批准号:7458146
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2007
-
负责人:John K Buolamwini
-
依托单位:
Nucleoside Transporters In HAART Mitochondrial Toxicity
-
批准号:7052119
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2005
-
负责人:John K Buolamwini
-
依托单位:
Nucleoside Transporters In HAART Mitochondrial Toxicity
-
批准号:6947653
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2005
-
负责人:John K Buolamwini
-
依托单位:
NUCLEOSIDE TRANSPORT INHIBITORS FOR CANCER PREVENTION
-
批准号:6878392
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2004
-
负责人:John K Buolamwini
-
依托单位: